6-K
Regentis Biomaterials Ltd. (RGNT)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
Form6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of January 2026
Commission file number: 001-42834
REGENTISBIOMATERIALS LTD.
(Translation of registrant’s name into English)
60Medinat Hayehudim Street, 4676652, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
On December 31, 2025, Dr. Eli Hazum resigned as the Chief Executive Officer of Regentis Biomaterials Ltd. (the “Company”) effective immediately. Dr. Hazum has indicated his resignation is for personal reasons and not due to any disagreement with the Company.
On the same day, the Company appointed Dr. Ehud Geller, the Chairman of the Company’s board of directors, as Chief Executive Officer.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Regentis Biomaterials Ltd. | ||
|---|---|---|
| Date: January 6, 2026 | By: | /s/<br> Dr. Ehud Geller |
| Name: | Dr. Ehud Geller | |
| Title: | Chairman and Chief Executive Officer |
2